Search
Prelude Therapeutics Inc
PRLDAdd to Watchlist
3.880USD
-0.220-5.37%
Close 10-30 16:00（ET）
309.62MMarket Cap
LossP/E TTM
Prelude Therapeutics Inc (PRLD) Stock Price Target & Forecast
Analyst Rating
Based on 5 analysts giving stock ratings to Prelude Therapeutics Inc in the past month.
Buy
1 Strong Buy
4 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
8.500USD+105.31%
PRLD Analyst Recommendation Trends
In the current month, PRLD has received 4 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. PRLD average Analyst price target in the last month is 8.500.
2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
1
1
1
1
1
1
1
1
4
4
2
2
2
2
2
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5
5
3
3
3
3
3
3
PRLD Analyst Rating for Peer Comparison
Updated: Nov 1, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
argenx SE
ARGX
10
14
3
0
0
27
Beigene Ltd
ONC
8
19
0
0
0
27
Insmed Inc
INSM
7
18
0
0
0
25
Revolution Medicines Inc
RVMD
10
14
1
0
0
25
Ionis Pharmaceuticals Inc
IONS
6
14
5
0
0
25
Kymera Therapeutics Inc
KYMR
9
13
2
0
0
24
IQVIA Holdings Inc
IQV
8
12
3
0
0
23
CRISPR Therapeutics AG
CRSP
4
8
11
0
0
23
Tempus AI Inc
TEM
4
7
11
0
1
23
Biontech SE
BNTX
4
11
8
0
0
23
Financial Forecasting
Based on analysts' estimates, PRLD EPS is projected to reach 0.038 in FY2026Q3, following reported EPS of -0.141 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.03
-0.25
-0.20
0.04
-0.17
Actual
-0.21
-0.13
-0.14
--
--
Surprise
-611.93%
+49.32%
+28.06%
--
--
FAQs
What is Prelude Therapeutics Inc's expected revenue for the next quarter?
Prelude Therapeutics Inc's expected revenue is 29.00M.
What is Prelude Therapeutics Inc's price target?
Analysts forecast that Prelude Therapeutics Inc's price target is USD 8.50, with the highest forecast at USD 10.00 and the lowest forecast at USD 6.00.
How have Prelude Therapeutics IncPRLD's recent earnings per share performed?
The market expectation was USD -0.14, while Prelude Therapeutics IncPRLD's earnings per share (EPS) for the previous quarter was USD -0.13. EPS for the next quarter is expected at USD 0.04.
What is the analyst rating for Prelude Therapeutics Inc?
Based on the ratings of Prelude Therapeutics Inc's stock from 5 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.